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Acute heart failureAbstract Heart failure and preserved ejection fraction (HFpEF) is defined as heart failure symp-
toms and signs with a normal or near-normal ejection fraction (EF) with evidence of diastolic dys-
function. The few Middle Eastern studies that have been conducted were designed to compare
patients with heart failure reduced ejection fraction (HFrEF) and HFpEF.
The aim of this study was to study Saudi patients with HFpEF who presented with acute heart fail-
ure, and define their clinical characteristics and the signs and symptoms of heart failure, echocar-
diographic findings and medications at admission and at hospital discharge.
Methods: This is a prospective observational study in which patients were included following an
acute heart failure presentation with N-terminal pro-BNP (NT-proBNP) > 300 ng/L and left ven-
tricular ejection fraction (LVEF) > 50%. They were admitted to the coronary care unit of king
Saud medical city from the period of March 2015 to September 2015.
Results: 114 patients were enrolled in the study and assessed at acute admission. Of these, 4% died
on day one of admission.
The mean ± SD age of 109 included patients was 59 ± 8 years and 55% were women. Hyperten-
sion (64%), dyslipidemia (76%), atrial tachyarrhythmia (38%), prior heart failure (33%) and ane-
mia (35%), median NT-proBNP was 2490 ± 125 ng/l at admission. Mean (LVEF) was 61 ± 3,
mean LV mass index was 118 ± 11, mean E/e0 was 12.2 ± 2, and left atrial volume index was
47 ± 7 mL/m2. Mean global left ventricular strain was 13.5 ± 1.5. At discharge the majority of
patients were still symptomatic with high NT-proBNP 542 ± 266.
Conclusions: Patients with HFpEF were old with slight female dominance, a high rate of hyperten-
sion, diabetes, dyslipidemia and much comorbidity. LVEF was preserved despite depressed left ven-
tricular longitudinal and diastolic functions with high filling pressure. At discharge the patients were
still symptomatic calling for further research to reach the best strategy for proper management.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ail.com
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2 S. Abohammar et al.1. Introduction
Heart failure (HF) is a complex medical syndrome with high
rates of mortality and morbidity across the world, and has a
significant negative impact on quality of life, healthcare costs,
and longevity despite recent improvements of its treatment.1,2
The incidence of HF is approximately 1–2% of the adult pop-
ulation, with the prevalence rising up to 10% among persons
70 years of age or older.3–5
In the recent years, heart failure with preserved ejection
fraction (HFpEF) has been increasingly recognized as a patho-
physiological entity.6 The proportion of patients with heart
failure with HFpEF is about 50% of the general heart failure
population.7–9 In epidemiological surveys, the prognosis of
HFpEF is nearly as poor as for heart failure with reduced ejec-
tion fraction (HFrEF).10–13
Although heart failure with preserved ejection fraction
(HFpEF) is defined as heart failure symptoms and signs with
a normal or near-normal EF with evidence of diastolic dys-
function14,15 current guidelines highlight the importance of
additional objective criteria to signs and symptoms and pre-
served or normal ejection fraction for the diagnosis of
HFpEF.16–18 These criteria include normal left ventricular vol-
ume, increased left atrial volume, left ventricular hypertrophy
and/or diastolic dysfunction and natriuretic peptides.19
HFpEF patients’ demographics, comorbid conditions,
prognosis, and response to therapies differ from those with
heart failure reduced ejection fraction (HFrEF).18
However several studies have been conducted in western
countries differentiating features of epidemiology, treatment,
and outcomes among patients with preserved and reduced
EF.20–22 Scarce data are available in the middle-east popula-
tions in general and Saudi patients in particular, who have
different etiology, ethnic, cultural backgrounds and risk fac-
tors from those patients in the west.14,23,24 The few Middle
Eastern Studies that have been conducted were designed
either to detect the prevalence and etiology of HFpEF or
to compare the prevalence, demography and comorbidity of
patients with HFrEF and HFpEF,12,15,23–26 so, the aim of
this study was to study Saudi patients with HFpEF who pre-
sented with acute heart failure, and define their clinical char-
acteristics and the signs and symptoms of heart failure,
echocardiographic findings and medications at admission
and at hospital discharge.2. Methods
This is a prospective observational study in which all
patients presented with acute heart failure with ejection
fraction >50% were included in the study. They were
admitted to the coronary care unit (CCU) of King Saud
Medical City from the period of March 2015 to September
2015.
The study was approved by the local ethics committee.
Inclusion criteria was acute presentation to the hospital
with clinical signs and symptoms of HF, according to the
Framingham criteria.27 NT-pro B type natriuretic peptide
(NT-pro-BNP)>300 pg/mL and left ventricular ejection frac-
tion (LVEF) > 50% by echocardiography performed within
the first 72 h.Please cite this article in press as: Abohammar S et al. Baseline characteristics of pa
heart failure in Saudi Arabia, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j2.1. Exclusion criteria
All conditions known to be associated with diastolic dysfunc-
tion such as infiltrative heart disease, hypertrophic cardiomy-
opathy, restrictive cardiomyopathy and constrictive
pericarditis, cor-pulmonale, severe mitral stenosis and mechan-
ical lesions need urgent open heart surgery as acute mitral
regurge had been excluded as well.
All inclusion criteria (clinical HF, EF, and peptide criteria)
were established within 72 h of presentation. Enrollment
occurred during this time or shortly thereafter, after the pres-
ence of any of the exclusion criteria has been ruled out.
Clinical data, including the medical history, cardiovascular
risk factors, and associate comorbidities, were collected from
the patients’ files.
The patients were followed up during their hospital stay
and complementary data were collected including chest radio-
graphy, electrocardiography (ECG), echocardiography, Dop-
pler, and laboratory tests.
The symptoms of patients were graded according to NYHA
classification.28
Blood samples were collected for analysis of (NT-pro-BNP)
on day 1 of admission and was repeated before discharge, and
complete laboratory investigations were performed as well.
A 12-lead surface ECG was recorded at 50 mm/s speed.
Interpretation was performed by a skilled investigator, and left
ventricular hypertrophy (LVH) was considered according to
Sokolow index.29
Echocardiography was performed using Vivid 7 (GE
Healthcare, Horten, Norway).
Two independent investigators analyzed the recordings
blinded to clinical data.
We calculated LV diameters by M-mode and LV EF by
Simpson’s biplane method. Right ventricular (RV) function
was assessed by tricuspid annular plane systolic excursion
(TAPSE) and tricuspid lateral annular systolic velocity (S0)
by pulsed tissue Doppler. Peak pulmonary arterial systolic
pressure (PASP) was estimated as the sum of peak RV-right
atrial gradient from the tricuspid valve regurgitant jet and
right atrial pressure on the basis of size and collapse of inferior
vena cava. The LV mass was estimated using the Penn formula
and normalized by the body surface area. Echocardiographic
LV hypertrophy was defined as an LV mass index > 134 g/
m2 for men and 110 g/m2 for women.30
LV longitudinal strains were analyzed by speckle tracking
echocardiography, with frame rateP 50 s. From apical four-
chamber, two-chamber, and long-axis view, peak longitudinal
strains from each of the 16 LV segments, either negative or
positive, were averaged automatically to LV global longitudi-
nal strain (GLS).31
Diastolic function parameters were measured as follows:
peak early diastolic filling (E) and late diastolic filling (A)
velocities, E/A ratio, E deceleration time, early diastolic septal
mitral annular velocity (e0) (averaged from three cardiac
cycles), and E/e0 as an index of LV filling pressure. Left atrial
volume index was calculated from apical four-and two-
chamber views, using area – length formula. Diastolic dysfunc-
tion was classified into four grades according to 2009 ASE
guidelines.32
Previous and current medications were reported from
studying the patients’ files.tients with heart failure and preserved ejection fraction at admission with acute
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Table 1 Clinical characters, ECG and X-ray findings of the patients during acute presentation and on
discharge.
Acute presentation At discharge
Age in years
Mean ± SD, range
59 ± 8, 39–78
Women 55%
BMI mean ± SD, range 27 ± 3, 23–36
HTN 64%
Smoking 26%
DM 64%
Dyslipidemia 76%
IHD 16%
VHD 8%
Kidney disease 20%
Prior stroke 6%
Prior HF admission 33%
COPD 25%
Dyspnea NYHA class
1 23%
2 65%
3 12%
4 100%
S3 64%
S4 87
LL edema 54% 20%
Hepatomegaly 31% 30%
Congested neck veins 80% 21%
Rales 100% 11%
FH 11%
Anemia 35%
SBPmmHg, mean ± SD, range 180 ± 29, 100–220 162 ± 25, 110–150
DBP mmHg mean ± SD, range 80 ± 10, 60–110 81 ± 11, 67–76
HR b/m mean ± SD, range 120 ± 9, 110–130 80 ± 6, 68–90
O2 SAT mean ± SD 90 ± 4 98 ± 2
LVH 21% 21%
LBBB 2% 2%
RBBB 6% 5%
Ventricular arrythmia 1% 0.05%
Atrial arrythmia 38% 19%
NT-pro-BNP pg/ml, mean ± SD, range 2490 ± 125, 600–2900 542 ± 266, 478–700
Pulmonary edema on X-ray 65% 11%
BMI = body mass index, HTN= hypertension, DM= diabetes mellitus, IHD= ischemic heart disease,
VHD= valvular heart disease, HF = heart failure, COPD= chronic obstructive pulmonary disease, LL = lower
limbs, NYHA=New York heart association, FH= family history of heart disease, SBP = systolic blood pressure,
DBP = diastolic blood pressure, HR= heart rate, LVH= left ventricular hypertrophy, LBBB= left bundle branch
block, RBBB= right bundle branch block, NT-pro-BNP= N-terminal pro brain natriuretic peptide.
Baseline characteristics of patients with heart failure and preserved ejection fraction at admission 32.2. Statistical analysis
All analyses were performed using EXCEL data sheet,
Microsoft office 2011. Continuous variables were presented
as means ± standard deviations (SDs). Categorical variables
are presented as counts and percentages, Student’s T test was
used to compare variables at admission and discharge, and a
p value < 0.05 is considered significant.
3. Results
A total of 586 patients with clinical evidence of heart failure
were admitted during the enrollment period.
152 patients were found to have HFpEF, 38 of them were
excluded as follows: 22 of them had severe aortic stenosis, 7Please cite this article in press as: Abohammar S et al. Baseline characteristics of pa
heart failure in Saudi Arabia, The Egypt Heart J (2016), http://dx.doi.org/10.1016/jhad prosthetic valve dysfunction, 4 had hypertrophic obstruc-
tive cardiomyopathy (HOCM), 2 had restrictive cardiomyopa-
thy (RCM), 2 had cor-pulmonale and 1 had constrictive
pericarditis.
114 patients were enrolled in the study and assessed on
acute admission. Of these, 5 patients (4%) died on day one
of admission so 109 patients were admitted to hospital for
heart failure management and were followed up during the
period of admission which ranged from 2 to 7 days with the
average of 5 days.3.1. Characteristics at acute admission
The mean age was 59 ± 8, 102/109 (94%) of the patients were
older than 55 years, they were more often females as theytients with heart failure and preserved ejection fraction at admission with acute
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Table 2 Laboratory findings of the patients during admission.
Parameter Mean ± SD Range
HbA1c % 7 ± 1 5.7–10
Total cholesterol mmol/L 5.5 ± 0.8 3.9–7.2
Triglycerides mmol/L 2.5 ± 1.3 1.3–5.8
HDL mmol/L 1.28 ± 0.29 0.75–1.76
LDL mmol/L 5.1 ± 0.7 3.8–6.5
HBG gm% 12.5 ± 1.6 9.9–14
TSH uU/ml 3.5 ± 0.9 2.5–6.8
Serum creatinine mg% 1.18 ± 0.5 1–2.2
HbA1c = hemoglobin A1c, HDL= high density lipoprotein,
LDL= low density lipoprotein, HBG= hemoglobin,
TSH= thyroid stimulating hormone.
Table 3 Echocardiographic criteria of the patients during
admission.
Parameter Mean ± SD Range
LAD cm 4 ± 0.4 3.2–4.6
LAVI mL/m2 47 ± 7 37–68
ESD CM 3.8 ± 2 2.8–4.1
EDD CM 5.6 ± 3.8 4.4–5.8
ESVI mL/m2 52.6 ± 6 20–65
EDVI mL/m2 105 ± 8 84–110
EF% 61 ± 3 53–64
FS% 32 ± 2.5 27–36
e cm/s 7 ± 3 5–12
E/A 1.6 ± 0.7 0.6–3.3
E deceleration time ms 206 + 76 200–302
E/e 12.2 ± 2 10–22
IVS cm 1 ± 0.1 0.8–1.3
LV mass index gm/m2 118 ± 17 90–178
RWMA 6%
ESPP mmHg 40 ± 5 32–50
TAPSE cm 1.5 ± 0.3 1.1–2.2
LV S cm/s 8 ± 0.7 7–12
RV S cm/s 10 ± 0.7 12–18
LV GLS% 13.5 ± 1.5 10 to 17
LAD= left atrial dimension, LAVI = left atrial volume index,
ESD= end systolic dimension, EDD= end diastolic dimension,
ESVI = end systolic volume index, EDVI = end diastolic volume
index, EF = ejection fraction, FS = fractional shortening,
IVS = inter-ventricular septum, LV= left ventricle, RV = right
ventricle, RWMA= regional wall motion abnormality,
ESPP = estimated systolic pulmonary pressure, TAPSE= tricus-
pid annular plane systolic excursion, GLS = global longitudinal
strain.
Table 4 Medications used by the patients at acute admission
and at discharge.
Medications At admission total 36
patients
At discharge total 109
patients
BB % 33 66
ACEI % or
ARBs
23 74
DIU % 67 100
Spironolactone
%
11 0
NO3 % 8 8
Digitalis % 1.2 0.5
Warfarin % 5 5
Statins % 54 70
Amiodarone % 2 2
NOAC % 1 7
ASA % 69 69
CCB % 14 23
BB = beta blockers, ACEI = angiotensin converting enzyme
inhibitor, ARBS = angiotensin receptor blockers, DIU= diuret-
ics, NO3 = nitrates, NOAC= new oral anticoagulants,
ASA= acetyl salicylic acid, CCB= calcium channel blockers.
4 S. Abohammar et al.constituted 55% of the patients (61/109), 55/61 (91%) of them
were postmenopausal, and 2/61 (3%) were using oral contra-
ceptive pills. 56/109 (51%) were overweight while 23/109
(21%) were obese. They have high prevalence of dyslipidemia,
hypertension and diabetes. Coronary heart disease (CAD) was
less prevalent among the patients 17/109 (16%). Few patients
have valvular heart disease; 9/109 (8%) patients in total, 5 of
them have aortic sclerosis with mild aortic stenosis, and 3 have
moderate to severe mitral regurge due to mitral annular calci-
fication (MAC) with no significant trans-mitral gradient and
one patient with mitral valve replacement. Some of the patientsPlease cite this article in press as: Abohammar S et al. Baseline characteristics of pa
heart failure in Saudi Arabia, The Egypt Heart J (2016), http://dx.doi.org/10.1016/jshowed comorbidity as chronic obstructive pulmonary disease
(COPD), renal diseases, anemia and prior stroke. Baseline cri-
teria are listed in Table 1. 11/21 (52%) of the renal patients
were treated with regular dialysis and 3/109 (3%) of the
patients were diagnosed with hypothyroidism on hormone
replacement.
On acute presentation all patients were presented with dys-
pnea New York Heart Association (NYHA) class IV. 36/109
(33%) of them have prior admission to the hospital with heart
failure diagnosis while 94/109 (87%) have history suggesting
heart failure before the exacerbation of acute heart failure.
All patients had rales while most of them showed congested
neck veins 87/109 (80%), 66/109 (60%) of the patients had sev-
ere hypertension; SBP > 180 mmHg and 90/109 (82%) were
tachycardic; HR > 100 b/m. Clinical signs and symptoms
are shown in Table 1. 41/109 (38%) of patients showed atrial
arrhythmia, 34/41(85%) who constituted to 31% of all
patients (109) had atrial fibrillation on acute presentation
and only 22/109 (21%) showed increased left ventricular
(LV) voltage criteria. ECG criteria are shown in Table 1.
N-terminal pro-Brain natriuretic peptide (NT-proBNP)
was significantly high on acute admission in 96% of patients.
37/109 (34%) of the patients had HbA1c > 7%, 20/109
(19%) showed hemoglobin < 12 gm% in men and <11 gm
% in women, 19/109 (17%) had serum creatinine > 1.1 mg
%, 10/109 (10%) had total cholesterol > 5.2 mmol/l and
2/109 (1.8%) had serum TSH> 6 uU/ml%.
Laboratory findings during hospital stay are shown in
Table 2.
None of the patients suffered from acute coronary syn-
drome at acute admission.
3.2. Echocardiographic measurements
Ejection fraction was >50% in all patients.
Left ventricular fractional shortening was >30% for most
patients (69/109; 63%). Left ventricular s’ was >7 cm/s fortients with heart failure and preserved ejection fraction at admission with acute
.ehj.2016.08.002
Table 5 Baseline criteria of patients included in the current
study, in Dubai,25 in PREVEND34 and in KaRen33 studies.
This study Dubai25 PREVEND34 KaRen33
Total number 109 106 125 539
Age 59 ± 8 67 ± 15 63 + 9 77 ± 9
Females 55 59 52 56
BMI > 25 71 63 32 > 30a
HTN 64 77 75 78
DM 64 63 12 30
Dyslipidemia 76 22 42
Smoking 26 22 25
Prior HF 33 83 New onset 40
AF 31 33 5 44
CAD 16 46 19 29
Anemia 35 79 37
Hospital stay 5 6 5
COPD 25 26 14
Mortality 4 6 2.4
DM= diabetes mellitus, HTN= hypertension, AF= atrial fib-
rillation, CAD= coronary artery disease, COPD= chronic
obstructive pulmonary disease.
a 32% of the patients had BMI > 30.
Baseline characteristics of patients with heart failure and preserved ejection fraction at admission 559/109 (53%). Left ventricular global longitudinal strain
(GLS) was <16% for 78/109 (71%). A total of 80/109
patients (73%) showed no significant left ventricular enlarge-
ment as left ventricular end-diastolic volume 697 mL/m2.
81/109 (73%) had concentric LVH.
Left atrial dimension (LAD) was > 4 cm in 45/109 (41%),
left atrial volume index (LAVI) was > 40 mL/m2 in 59/109
(55%), LV mass index (LVMI) > 122 gm/m2 in women and
>149 in men in 55/109 (51%) of all patients, E/e0 ratio
was > 15 in 24/109 (22%), E/e> 12 was in 67/109 (61%), e0
wave was < 11 cm/s for 98/109 (89%) patients while estimated
systolic pulmonary pressure (ESPP) was > 35 mmHg in
72/109 (66%) of the patients, and only 11 of 109 (10%) had
RV s less than 12 cm/s. 43/109 (40%) of patients had grade
1 diastolic dysfunction, 59/109 (54%) had grade 2 and 7/109
(6%) had grade 3 diastolic dysfunction. Echo criteria are listed
in Table 3.
3.3. Medication
36/109 (33%) of patients were receiving medications prior to
admission, and the most commonly prescribed medications
were aspirin followed by diuretics 69%, 67% simultaneously.
On discharge all patients received medications; diuretics
was for all, 74% received either ACEI or ARBs, 12% were
receiving spironolactone on admission and were discontinued
on discharge, statin use increased from 54% to 70%, and also
NOAC use increased from 1% to 7% for stroke prevention in
atrial fibrillation (SPAF).
5/109 (5%) received warfarin, 4 patients for SPAF and one
patient for mitral valve (MV) replacement Table 4.
On admission 87% were chronic users for non-steroidal
anti-inflammatory drugs (NSAI), 53% for proton pump inhi-
bitors (PPI), 20% for iron supplements, 3% for thyroxin,
and 10% for renal support medications.
On discharge NSAI prescription decreased to 33%, and
PPI increased to 67%.
3.4. On discharge
Most patients were still symptomatic (65%) in NYHA class 2,
few patients were still having fine basal rales and less patients
had AF 20/109 (19%) and significantly less NT-pro-BNP level
p= 0.0002 Table 1.
4. Discussion
This study prospectively included a population of HFpEF
patients as strictly defined by validated Framingham criteria,
preserved ejection fraction and elevated natriuretic peptides,
and they were studied at admission with AHF and during hos-
pital admission till discharge. They were elderly (59 ± 8), and
showed a high proportion of female gender 55%, dyslipidemia,
diabetes, hypertension and high mean weight. They suffered
from multiple comorbidities such as chronic obstructive pul-
monary disease (COPD), chronic renal failure and anemia;
atrial fibrillation was the most common arrhythmia found in
our patients and only few patients had a history of coronary
artery disease (CAD).
Most of the researches studying HFpEF patients in western
countries33,34 had older population, but this is not true inPlease cite this article in press as: Abohammar S et al. Baseline characteristics of pa
heart failure in Saudi Arabia, The Egypt Heart J (2016), http://dx.doi.org/10.1016/jresearches done in the gulf because of the early occurrence
of more prevalent diabetes mellitus.14,26
Women constituted the main bulk of the patients of
HFpEF33,34,37 and this is probably due to the fact that gender
affects cardiac remodeling. When confronted with pressure
overload, the LV hypertrophies more and dilates less in women
than in men.35 A reduced rate of myocyte loss in women and
transcriptional regulation by estrogens of genes implicated in
cardiac hypertrophy may contribute to persistent gender
related differences in cardiac remodeling.36
25% of our patients had COPD and asthma comparable to
another research done in the gulf (Dubai trial)25 but was less
often reported in KaRen study33 and this may be due to lower
smoking rate.
The investigators of the PREVEND trial34 found out that
19% of their patients had CAD which agrees with our findings
in contrast to the patients of KaRen33 and Dubai25 trials who
had history of more CAD, and this may be because of the
shorter inclusion period (6 months) in our study and the fact
that all the patients were recruited from one single hospital.
Our patients showed more prevalent dyslipidemia as com-
pared to all other studies25,33,34, most probably because they
were more obese and diabetics.
Atrial fibrillation was a frequent finding in our study, con-
sistent with other studies33,20,37, as it is a common cause of HF
precipitation in HFpEF38 Table 5.
33% of the patients were previously diagnosed with heart
failure, comparable to 40% in KaRen33 which is much lower
than in registries such as ADHERE20, CHARM-Preserved39
and Dubai25 possibly because of the shorter inclusion period
and the fact that all the patients were recruited from one single
hospital.
It seems that anemia is prevalent in HFpEF patients as
proved by our study and previous studies33,40 and it is associ-
ated with increased mortality.41
Few of our patients showed chronic kidney disease compa-
rable to previous studies.33,48 Chronic renal dysfunction istients with heart failure and preserved ejection fraction at admission with acute
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6 S. Abohammar et al.frequently associated with diastolic HF and has been shown to
independently increase mortality.42
At presentation, most of the patients presented with severe
hypertension due to the stress associated with AHF but during
hospital stay SBP readings were comparable to the previous
studies.25–33
Aspirin was utilized more frequently in patients at acute
admission possibly for primary prevention as fewer patients
were diagnosed with coronary artery disease.
Diuretics were more frequently prescribed at discharge for
symptoms control, statins prescription increased for primary
prevention as well as the prescription of ACEI or ARBs at dis-
charge given the fact that most of the patients were diabetics
and had increased left ventricular mass.43,44
Spironolactone prescription decreased as there is evidence
that spironolactone has no more benefit in the treatment of
HFpEF.45
CCBs prescription increased at discharge as they consti-
tuted the second or third line of treatment of uncontrolled
hypertension after diuretics and ACEI.46 At discharge beta-
blockers, diuretics, and blockers of the renin angiotensin sys-
tem were prescribed in similar proportions to previous
reports.47
At discharge the majority of patients were still symp-
tomatic, with evidence of pulmonary and systemic congestion
suggesting insufficient treatment of congestion at the acute
admission in spite of a mean hospital stay of 5 days and rela-
tively high usage of diuretics. More evidence for insufficient
therapy is the fact the NT-proBNP level remained high even
at discharge. It is natural to assume that one of the reasons
for this insufficient improvement is a lack of guideline-
indicated treatments besides diuretics and drugs for
hypertension.4.1. Echocardiographic characteristics
All patients had LVEF> 50%. Although they had normal
systolic indices, LV global strain was abnormal in the majority
of patients indicating a sort of subclinical systolic
dysfunction.50
Most patients had LVH and an increase in left ventricular
mass and these are very common findings in such population
of patients as they are older, more often women, and have a
high prevalence of hypertension, and a large number of comor-
bidities, each of which increase the risk for developing concen-
tric remodeling.51
They showed normal LV internal dimensions and volumes.
They also had diastolic dysfunction, high filling pressure and
increased LA volume index, and the majority of our patients
showed variable degrees of pulmonary hypertension, and mild
depression of RV longitudinal function. These findings are
comparable to the findings in other studies.33,11
Although all of our patients had variable degrees of dias-
tolic dysfunction 45% had normal LA volume index and that
was shown in I-PRESERVE,49 as well. LA size results from
both the extent and duration of increased LV diastolic pressure
so there was no atrial remodeling in these patients possibly
because the disease was early or the left ventricular end dias-
tolic pressure (LVEDP) was not high enough.Please cite this article in press as: Abohammar S et al. Baseline characteristics of pa
heart failure in Saudi Arabia, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j5. Limitations
(1) This study is limited to the assessment of HFpEF
patients during acute admission with no long term
follow-up.
(2) Patients were recruited only from one big hospital.
(3) The study may not represent the Saudi population
because other non-Saudi residents were included (only
few).
(4) Not all parameters of diastolic function assessment were
measured, and only the most validated ones were used.6. Conclusion
Patients with HFpEF were old (but younger than western
patients) with slight female dominance, a high rate of hyper-
tension, diabetes, dyslipidemia and much comorbidity. LVEF
was preserved despite depressed left ventricular longitudinal
and diastolic functions with high filling pressure. Patients dis-
charged from the hospital after acute admission were still
symptomatic due to lack of guidelines for the treatment of
HFpEF which calls for more research.
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